Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027

News provided by

04 Aug, 2023, 11:15 ET

Share this article

NEW YORK, Aug. 4, 2023 /PRNewswire/ -- The bioprocess validation market size to grow by USD 280.93 million between 2022 and 2027, and register a CAGR of 11.39%, according to Technavio's latest market research report estimates. With a focus on identifying dominant industry influencers, Technavio's reports present a detailed study by the way of synthesis, and summation of data from multiple sources. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. The report is segmented by end-user, type, and geography. North America is estimated to contribute 39% to the growth of the market during the forecast period. Growing demand for biopharmaceuticals and growing interest in product safety are the key factors of market growth in the region. Pfizer Inc (Pfizer), Merck Group (Merck), Biogen Inc (Biogen), and Amgen Inc (Amgen) are major players with a presence in the region. In addition, they develop biopharmaceuticals and invest in bioprocess validation activities to ensure product quality and safety. Hence, these factors are expected to drive market growth in the region during the forecast period. Technavio offers in-depth market insights that assist global businesses to obtain growth opportunities. Read Sample Report

The report also covers the following areas:

Bioprocess Validation Market 2023-2027: Segmentation

The market share growth by the pharmaceutical companies segment will be significant during the forecast period. Pfizer, Johnson, Johnson (J&J), and Novartis AG (Novartis) are some of the major pharmaceutical companies that are having a significant impact on the bioprocess validation market. This impact is due to their vast resources, expertise, and experience in this field. Furthermore, the development of complex and innovative biological products is one of the key contributions of major pharmaceutical companies to the bioprocess validation market. Hence, such factors are expected to drive the growth of this segment in the market during the forecast period.

Bioprocess Validation Market 2023-2027: Vendor Analysis and Scope

Some of the major vendors of the bioprocess validation market include Agilent Technologies Inc., Asahi Kasei Corp., Avantor Inc., Bangalore Biotech Labs Pvt. Ltd., Charles River Laboratories International Inc., Corning Inc., Danaher Corp., Eurofins Scientific SE, GEA Group AG, Hangzhou Cobetter Filtration Equipment Co. Ltd., Laboratory Corp. of America Holdings, Lonza Group Ltd., Meissner Filtration Products Inc., Merck KGaA, Porvair Plc, ProPharma Group Holdings LLC, Sartorius AG, SGS SA, Thermo Fisher Scientific Inc., and W. L. Gore and Associates Inc. To help businesses improve their market position, Technavio's report provides a detailed analysis of around 15+ vendors operating in the market.

Vendor Offering

Bioprocess Validation Market 2023-2027: Market Dynamics

Key Driver

The increasing demand for biopharmaceuticals is a key factor driving market growth. The demand for biopharmaceuticals in the healthcare sector is increasing. To ensure consistency, the production of high-quality products that deliver efficacy and patient safety can be achieved by validation. For example, the bioproduction of monoclonal antibodies is one of the major examples where validation of a biological process has a significant impact. In addition, a well-designed biological process validation plan is the most important factor in ensuring that the final product meets the required standards and regulatory specifications. Hence, these factors are expected to drive market growth during the forecast period.

Major Trends

The increasing adoption of single-use technologies is a major trend in the market. The ease of implementation for biological process validation is one of the main advantages offered by SUT. The use of SUT eliminates the need for cleaning and disinfection procedures, which can be time-consuming and costly. In addition, it provides greater flexibility in terms of scaling up and down because they can be easily discarded after use is one of the key features. Small biotech companies can benefit because they do not have the resources to invest in extensive cleaning and disinfection equipment. Therefore, these factors are expected to drive market growth during the forecast period.

Significant Challenges

High costs associated with bioprocess validation are a significant challenge restricting market growth. The three main categories for costs associated with biological process validation are equipment, personnel, and time. For example, specialized equipment, such as bioreactors, chromatographic systems, and mass spectrometers, among others are required to validate a biological process. These devices can be expensive or affordable to purchase, maintain, and calibrate. Hence, the high cost of bioprocess validation is expected to restrict market growth during the forecast period.

Drivers, Trends, and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report!

What's New? -

Bioprocess Validation Market 2023-2027: Key Highlights

Gain instant access to 17,000+ market research reports.Technavio's SUBSCRIPTION platform

Related Reports:The recombinant proteins market is estimated to grow at a CAGR of 9.46% between 2022 and 2027. The market size is forecast to increase by USD 650.96 million. Furthermore, this report extensively covers market segmentation by application (biotechnology research, drug discovery and development, biopharmaceutical production, and others), end-user (pharma and biotechnology companies, academic and research institutes, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). Growing opportunities from emerging economies is a key trend influencing the recombinant proteins market growth.

The biochips market is estimated to grow by USD 43,273.01 million between 2022 and 2027 accelerating at a CAGR of 25.15% during the forecast period. Furthermore, this report extensively covers market segmentation by end-user (biotechnology and pharmaceutical companies, hospitals and diagnostics centers, and academic and research institutes), technology (microarrays and microfluidics), and geography (North America, Europe, APAC, Middle East and Africa, and South America). The growing applications of microarray biochips in drug discovery is a key factor driving market growth during the forecast period.

Bioprocess Validation Market Scope

Report Coverage

Details

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 11.39%

Market growth 2023-2027

USD 280.93 million

Market structure

Fragmented

YoY growth 2022-2023(%)

11.23

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 39%

Key countries

US, Canada, Germany, China, and Japan

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Agilent Technologies Inc., Asahi Kasei Corp., Avantor Inc., Bangalore Biotech labs Pvt. Ltd., Charles River Laboratories International Inc., Corning Inc., Danaher Corp., Eurofins Scientific SE, GEA Group AG, Hangzhou Cobetter Filtration Equipment Co. Ltd., Laboratory Corp. of America Holdings, Lonza Group Ltd., Meissner Filtration Products Inc., Merck KGaA, Porvair Plc, ProPharma Group Holdings LLC, Sartorius AG, SGS SA, Thermo Fisher Scientific Inc., and W. L. Gore and Associates Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by End-user

7 Market Segmentation by Type

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Vendor Landscape

12 Vendor Analysis

13 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [email protected]Website: www.technavio.com

SOURCE Technavio